文献速递前列腺癌

转移性去势抵抗性前列腺癌患者中[177Lu]Lu-PSMA-617 3期VISION试验的安全性分析

Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.
PubMed 文献 · Eur Urol · 2024-01-06

VISION是一项国际开放标签研究,患者按2:1随机接受177Lu-PSMA-617联合标准治疗或单纯标准治疗。分析显示接受≤4周期与5-6周期治疗的患者任何级别治疗中出现的不良事件(TEAE)发生率相似,延长暴露至6周期未增加毒性风险,支持6周期177Lu-PSMA-617的良好获益-风险特征。

要点

  • 第1-4周期与第5-6周期的任何级别TEAE发生率相似,各周期TEAE频率相近。
  • 接受>4周期的患者未报告新的安全性问题。
  • 延长177Lu-PSMA-617联合标准治疗暴露未与更高毒性风险相关。

核心结论

  • 延长177Lu-PSMA-617联合标准治疗的暴露未与更高毒性风险相关,较长的安全性观察时间可解释与单纯标准治疗相比更高的TEAE发生率。
  • 研究结果支持在该设置下6周期177Lu-PSMA-617具有良好的获益-风险特征,并支持对临床获益且耐受该治疗的患者使用最多6周期177Lu-PSMA-617。

研究设计与样本

  • VISION是一项国际、开放标签研究,患者按2:1随机接受177Lu-PSMA-617联合标准治疗或单纯标准治疗。
  • 在预设亚组中评估接受≤4周期与5-6周期治疗的患者以及每个治疗周期中治疗中出现的不良事件(TEAE)发生率。
  • TEAE发生率还按治疗暴露进行调整,计算每100患者治疗观察年的发生率,分析针对TEAE的首次发生。

主要发现

  • 第1-4周期与第5-6周期的任何级别TEAE发生率相似,177Lu-PSMA-617治疗所有周期的TEAE频率相似。
  • 接受>4周期的患者未报告额外的安全性问题。
  • 暴露调整的安全性分析显示两臂总体TEAE发生率相似,但不同TEAE类型呈现不同趋势,且与177Lu-PSMA-617相关的事件发生率在177Lu-PSMA-617臂仍更高。

临床怎么用

  • 作者认为,研究结果支持在该设置下6周期177Lu-PSMA-617的良好获益-风险特征,并支持对临床获益且耐受该治疗的患者使用最多6周期177Lu-PSMA-617。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) plus the standard of care (SoC) significantly improved overall survival and radiographic progression-free survival versus SoC alone in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer in the VISION trial. We evaluated the safety of additional cycles of 177Lu-PSMA-617 and the impact of longer observation time for patients receiving 177Lu-PSMA-617 plus SoC. METHODS: VISION was an international, open-label study. Patients were randomised 2:1 to receive 177Lu-PSMA-617 plus SoC or SoC alone. The incidence of treatment-emergent adverse events (TEAEs) was assessed in prespecified subgroups of patients who received ≤4 cycles versus 5-6 cycles of treatment and during each cycle of treatment. The TEAE incidence was also adjusted for treatment exposure to calculate the incidence per 100 patient-treatment years of observation. This analysis was performed for the first occurrence of TEAEs. KEY FINDINGS AND LIMITATIONS: The any-grade TEAE incidence was similar in cycles 1-4 and cycles 5-6. TEAE frequency was similar across all cycles of 177Lu-PSMA-617 treatment. No additional safety concerns were reported for patients who received >4 cycles. The exposure-adjusted safety analysis revealed that the overall TEAE incidence was similar between arms, but distinct trends for different TEAE types were noted and the incidence of events associated with 177Lu-PSMA-617 remained higher in the 177Lu-PSMA-617 arm. CONCLUSIONS AND CLINICAL IMPLICATIONS: Longer exposure to 177Lu-PSMA-617 plus SoC was not associated with a higher toxicity risk, and the extended time for safety observation could account for the higher TEAE incidence in comparison to SoC alone. The findings support a favourable benefit-risk profile for 6 cycles of 177Lu-PSMA-617 in this setting and the use of up to 6 cycles of 177Lu-PSMA-617 in patients who are clinically benefiting from and tolerating this therapy. PATIENT SUMMARY: For patients with metastatic prostate cancer no longer responding to hormone therapy, an increase in the number of cycles of treatment with a radioactive compound called 177Lu-PSMA-617 from four to six had no additional adverse side effects.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Chi KN, Armstrong AJ, Krause BJ, et al. Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2024. PMID: 38185538. doi:10.1016/j.eururo.2023.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。